IDEXX Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de IDEXX Laboratories' es Jay Mazelsky , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $11.52M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.098% de las acciones de la empresa, por valor de €37.56M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 7.5 años, respectivamente.

Información clave

Jay Mazelsky

Chief Executive Officer (CEO)

US$11.5m

Compensación total

Porcentaje del salario del CEO	8.7%
Permanencia del CEO	4.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	7.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Mazelsky en comparación con los beneficios de IDEXX Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$867m
Dec 31 2023	US$12m	US$1m	US$845m
Sep 30 2023	n/a	n/a	US$823m
Jun 30 2023	n/a	n/a	US$791m
Mar 31 2023	n/a	n/a	US$699m
Dec 31 2022	US$10m	US$1m	US$679m
Sep 30 2022	n/a	n/a	US$670m
Jun 30 2022	n/a	n/a	US$664m
Mar 31 2022	n/a	n/a	US$735m
Dec 31 2021	US$9m	US$977k	US$745m
Sep 30 2021	n/a	n/a	US$757m
Jun 30 2021	n/a	n/a	US$728m
Mar 31 2021	n/a	n/a	US$674m
Dec 31 2020	US$7m	US$814k	US$582m
Sep 30 2020	n/a	n/a	US$497m
Jun 30 2020	n/a	n/a	US$460m
Mar 31 2020	n/a	n/a	US$437m
Dec 31 2019	US$7m	US$632k	US$428m
Sep 30 2019	n/a	n/a	US$423m
Jun 30 2019	n/a	n/a	US$407m
Mar 31 2019	n/a	n/a	US$390m
Dec 31 2018	US$3m	US$555k	US$377m
Sep 30 2018	n/a	n/a	US$330m
Jun 30 2018	n/a	n/a	US$307m
Mar 31 2018	n/a	n/a	US$284m
Dec 31 2017	US$2m	US$469k	US$263m

Compensación vs. Mercado: La compensación total de Jay($USD11.52M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Jay ha sido consistente con los resultados de la empresa en el último año.

CEO

Jay Mazelsky (62 yo)

4.9yrs

Permanencia

US$11,519,309

Compensación

Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Mazelsky	President	4.9yrs	US$11.52m	0.099% $ 37.9m
Brian McKeon	CFO, Executive VP & Treasurer	10.3yrs	US$3.85m	0.035% $ 13.6m
Michael Lane	Executive VP and GM of Reference Laboratories & Information Technology	4.3yrs	US$2.92m	0.0085% $ 3.3m
John Hart	Senior Vice President of Global Operations	6.7yrs	sin datos	sin datos
Jeffery Chadbourne	Senior Vice President of Commercial Finance & Sales Operations	9.3yrs	sin datos	sin datos
Martin Smith	Executive VP & CTO	2.8yrs	sin datos	sin datos
Ken Grady	Senior VP & Chief Information Officer	8.3yrs	sin datos	sin datos
Sharon Underberg	Executive VP	no data	US$1.88m	0.0068% $ 2.6m
Michael Johnson	Executive VP & Chief Human Resources Officer	2.2yrs	sin datos	0.00022% $ 84.4k
George Fennell	Senior VP & Chief Revenue Officer	no data	sin datos	0.0084% $ 3.2m
Kerry Bennett	Senior VP and GM of Product & Strategy of Global Reference Labs	less than a year	sin datos	sin datos
Michael Erickson	Executive VP and GM of Point of Care Diagnostics & Telemedicine	no data	sin datos	0.013% $ 5.0m

4.9yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IX1 se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Mazelsky	President	4.6yrs	US$11.52m	0.099% $ 37.9m
M. Szostak	Independent Director	11.8yrs	US$367.66k	0.0079% $ 3.0m
Daniel Junius	Independent Director	10.2yrs	US$362.66k	0.0031% $ 1.2m
Bruce Claflin	Independent Director	8.8yrs	US$367.66k	0.0023% $ 894.3k
Jonathan Ayers	Non-Employee Director	22.3yrs	US$335.16k	0.70% $ 268.6m
Stuart Essig	Independent Director	6.8yrs	US$350.16k	0.0024% $ 917.4k
Lawrence Kingsley	Independent Non-Executive Chairman	7.6yrs	US$495.02k	0.0095% $ 3.7m
Sophie Vandebroek	Independent Director	10.8yrs	US$335.16k	0.011% $ 4.2m
Irene Chang Britt	Independent Director	less than a year	US$258.89k	0.00025% $ 96.0k
Sam Samad	Independent Director	4.8yrs	US$342.66k	0% $ 0
Asha Collins	Independent Director	3.5yrs	US$335.16k	0.00094% $ 360.8k

7.6yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de IX1 se considera experimentada (7.5 años de antigüedad promedio).

IDEXX Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

Executive VP & Chief Commercial Officer recently sold €2.8m worth of stock

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Independent Director recently sold €862k worth of stock

Recent updates

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold €2.8m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$2.70 (vs US$1.57 in 2Q 2022)

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Independent Director recently sold €862k worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

Full year 2022 earnings released: EPS: US$8.12 (vs US$8.74 in FY 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Third quarter 2022 earnings released: EPS: US$2.17 (vs US$2.06 in 3Q 2021)

Insufficient new directors

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$1.57 (vs US$2.37 in 2Q 2021)

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold €112k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

Executive VP & Chief Commercial Officer recently sold €2.6m worth of stock

Third quarter 2021 earnings released: EPS US$2.06 (vs US$1.71 in 3Q 2020)

President recently sold €3.4m worth of stock

Insider recently sold €6.0m worth of stock

Second quarter 2021 earnings released: EPS US$2.37 (vs US$1.75 in 2Q 2020)

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Chief Marketing Officer & Senior VP recently sold €916k worth of stock

Chief Marketing Officer & Senior VP recently sold €1.3m worth of stock

Independent Director has left the company

Senior Advisor & Director recently sold €227k worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

New 90-day high: €463

Independent Director recently sold €135k worth of stock

Dr. Rebecca M. Henderson Intends to Retire from the Board of Directors of IDEXX Laboratories, Inc

Independent Director recently sold €4.9m worth of stock

Full year 2020 earnings released: EPS US$6.82 (vs US$4.97 in FY 2019)

Revenue beats expectations

New 90-day high: €424

­­IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative

IDEXX Laboratories, Inc. to Report Q4, 2020 Results on Feb 02, 2021

Idexx Laboratories, Inc. Elects Asha S. Collins as an Independent Class I Director

New 90-day high: €406

Senior Advisor & Director recently sold €7.6m worth of stock

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

IDEXX Laboratories, Inc. and the Tuskegee University College of Veterinary Medicine Announce Initiative